The 1st International standard for transforming growth factor-β3 (TGF-β3).

[1]  D. J. Finney.  Statistical Method in Biological Assay , 1966 .

[2]  T. Kirkwood,et al.  Design and analysis of accelerated degradation tests for the stability of biological standards II. A flexible computer program for data analysis. , 1984, Journal of biological standardization.

[3]  J. Massagué,et al.  The antiproliferative effect of type beta transforming growth factor occurs at a level distal from receptors for growth-activating factors. , 1986, The Journal of biological chemistry.

[4]  Sporn,et al.  Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. , 1988, The Journal of biological chemistry.

[5]  M. Sporn,et al.  Transforming Growth Factor‐β: Multifunctional Regulator of Cell Growth and Phenotype , 1988, Annals of the New York Academy of Sciences.

[6]  K. Miyazono,et al.  Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. , 1988, The Journal of biological chemistry.

[7]  R. Derynck,et al.  A new type of transforming growth factor‐beta, TGF‐beta 3. , 1988, The EMBO journal.

[8]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Wadhwa,et al.  A novel, sensitive bioassay for transforming growth factor beta. , 1994, Journal of immunological methods.

[10]  M. Wadhwa,et al.  A novel, sensitive bioassay for transforming growth factor β , 1993 .

[11]  S. Inui,et al.  An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct , 1994 .

[12]  V. Kaartinen,et al.  Abnormal lung development and cleft palate in mice lacking TGF–β3 indicates defects of epithelial–mesenchymal interaction , 1995, Nature Genetics.

[13]  M. Ferguson,et al.  Transforming growth factor-beta 3 is required for secondary palate fusion. , 1995, Nature genetics.

[14]  M. Ferguson,et al.  Transforming growth factor–β3 is required for secondary palate fusion , 1995, Nature Genetics.

[15]  T. Wyss-Coray,et al.  Highly sensitive and specific bioassay for measuring bioactive TGF-β , 2006, BMC Cell Biology.

[16]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[17]  Jinghua Hao,et al.  TGF-beta3: A promising growth factor in engineered organogenesis. , 2008, Expert opinion on biological therapy.

[18]  Jinghua Hao,et al.  TGF-β3: A promising growth factor in engineered organogenesis , 2008 .

[19]  D. Bending,et al.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. , 2009, The Journal of clinical investigation.

[20]  M. Ferguson,et al.  Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies , 2009, The Lancet.

[21]  M. Korpal,et al.  Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. , 2010, European journal of cancer.

[22]  Dongan Wang,et al.  Effects of combinational adenoviral vector‐mediated TGFβ3 transgene and shRNA silencing type I collagen on articular chondrogenesis of synovium‐derived mesenchymal stem cells , 2010, Biotechnology and bioengineering.

[23]  A. Tandon,et al.  Role of transforming growth factor Beta in corneal function, biology and pathology. , 2010, Current molecular medicine.